TIDMAGY

Allergy Therapeutics PLC

07 March 2018

Hardman Research: Clinical development towards submission

Clinical development towards submission: AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) Grass, the subcutaneous allergy immunotherapy (AIT), continues to gain market share despite being available in the EU only on a 'Named Patient' basis. The Phase III trial, designed to obtain approval for PQ Birch as a biologic in Europe, is well advanced, and the Phase II PQ Grass trial will report data shortly. As explained in the February trading update, underlying 1H'18 sales growth, although weaker than expected due to a low pollen season in central Europe, suggests that AGY has continued to make market share gains.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/allergy-therapeutics-documents/agy---interims---7th-march-2018.pdf

 
 To contact us:          Contacts:       mh@hardmanandco.com 
  Hardman & Co            Dr Martin       dmh@hardmanandco.com 
  35 New Broad Street     Hall            gp@hardmanandco.com 
  London                  Dr Dorothea 
  EC2M 1NH                Hill 
  www.hardmanandco.com    Dr Gregoire 
  Follow us on Twitter    Pave 
  @HardmanandCo 
 
                          +44 20 7194 
                          7622

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAUGUBGWUPRGQQ

(END) Dow Jones Newswires

March 07, 2018 04:30 ET (09:30 GMT)

Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Allergy Therapeutics Charts.
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Allergy Therapeutics Charts.